News
Elvie announces new features for electric breast pump app
Elvie has launched new features on its app after customers’ feedback.
Firstly launched at the beginning of August, Elvie Stride – the new electric breast pump – has now introduced an ‘on fed alert’ and more informative content on the app’s feed.
Users will now receive alerts from the app smart features, allowing them to make the most of their pumping sessions.
The app has now more engaging and informative content to guide the user through their pumping journey and to make the use more immersive.
The app has also introduced a more extensive questions area, where Elvie Customer Care service allow the users to always be in contact with experts.
Elvie Stride sits under clothing and does not have any charging wires. Users can also connect their Elvie Stride to the free Elvie app, which allows them to control the pump remotely, save preferred settings and track pumping history.
CEO and co-founder of Elvie, Tania Boler said: “Our goal is to empower and enable women to achieve everything their bodies are capable of, and develop an ecosystem of high tech products to match the high spec needs of women’s bodies.
“There is still a lot of stigma and challenges associated with breastfeeding and pumping.
“Elvie Stride gives more women the opportunity to pump discreetly and on their own terms.”
Why wireless pumps?

Elvie Stride
Wireless pumps have no wires connecting the woman to a power source, like a battery pack or an outlet, so that she can move around and not worry about staying in one place.
With wearable breast pumps, the user can wear them inside their bra, under their shirt, which means that they can be worn while during daily activities.
Wearable pumps are also very quiet which allows the user to wear them under their shirt without people even knowing that they’re pumping.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Wellness4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







Pingback: Femtech start-up partners with HSBC UK to accelerate growth - FemTech World